Jul 20, 2020 7:55am EDT Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
Jun 29, 2020 8:45am EDT Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
Jun 17, 2020 9:23am EDT Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
Dec 17, 2019 8:30am EST Lantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer
Dec 11, 2019 9:00am EST Lantern Pharma Expands and Strengthens Board of Directors with Healthcare and Pharma Industry Veterans Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D.
Nov 07, 2019 8:00am EST Lantern Pharma CEO Panna Sharma to Present & Participate in Panel Discussion at AI Applications in Biopharma Summit 2019 in Boston
Oct 29, 2019 8:00am EDT Lantern Pharma Selects Reprocell Inc. to Provide Preclinical Screening and Biomarker Discovery Services for Portfolio of Targeted Oncology Drugs
